Drug development in preeclampsia: a ‘no go’ area?

References

• Hoyert DL. Maternal mortality and related concepts. Vital Health Stat 3 2007;33:1–13.
   Google Scholar
• Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Siba BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2004;190:1590–1595; discussion 1595–1597.
   PubMed Web of Science ®Google Scholar
• Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, Simon NP, Wilson DC, Broyles S, Bauer CR, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 2000;105:1216–1226.
   PubMed Web of Science ®Google Scholar
• Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The cost of preterm birth throughout childhood in England and Wales. Pediatrics 2009;123:e312–e327.
   PubMed Web of Science ®Google Scholar
• Wing DA, Powers B, Hickok D. U.S. Food and Drug Administration drug approval: slow advances in obstetric care in the United States. Obstet Gynecol 2010;115:825–833.
   PubMed Web of Science ®Google Scholar
• Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med 2008;5:e22.
   PubMed Web of Science ®Google Scholar
• Sandrim VC, Palei ACT, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008;52:402–407.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–649.
   PubMed Web of Science ®Google Scholar
• Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361:1511–1517.
   PubMed Web of Science ®Google Scholar
• Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009;28:369–382.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?. Biochem Soc Trans 2009; 37(Pt 6):1237–1242.
   PubMed Web of Science ®Google Scholar
• Adair CD, Luper A, Rose JC, Russell G, Veille JC, Buckalew VM. The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial. J Perinatol 2009;29:284–289.
   PubMed Web of Science ®Google Scholar
• Adair CD, Buckalew VM, Graves SW, Lam GK, Johnson DD, Saade G, Lewis DF, Robinson C, Danoff TM, Chauhan N, et al. Digoxin Immune fab treatment for severe preeclampsia. Am J Perinatol 2010;27:655–662.
   PubMed Web of Science ®Google Scholar
• von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, Walley KR, Russell JA. Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? Crit Care Med 2002;30:1883–1892.
   PubMed Web of Science ®Google Scholar
• Unemori E, Sibai B, Teichman SL. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci 2009;1160:381–384.
   PubMed Web of Science ®Google Scholar
• de Belder A, Lees C, Martin J, Moncada S, Campbell S. Treatment of HELLP syndrome with nitric oxide donor. Lancet 1995;345:124–125.
   PubMed Web of Science ®Google Scholar
• de Belder AJ, MacAllister R, Radomski MW, Moncada S, Vallance PJ. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994;28:691–694.
   PubMed Web of Science ®Google Scholar
• Sayed N, Kim DD, Fioramonti X, Iwahashi T, Duran WN, Beuve A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 2008;103:606–614.
   PubMed Web of Science ®Google Scholar
• Lees C, Langford E, Brown AS, de Belder A, Pickles A, Martin JF, Campbell S. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol 1996;88:14–19.
   PubMed Web of Science ®Google Scholar